Advertisement
Head and Neck
A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck.
CASE 6316
View full trial information.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Leukemia, Chronic Lymphocytic (CLL)
A Disease Registry for Patients with Chronic Lymphocytic Leukemia.
PCYC 1915
View full trial information.
Anemia
A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA).
SYNT 1Z17
View full trial information.
Polycythemia Vera
A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients with Hydroxyurea-Resistant/Intolerant Polycythemia Vera.
ROCH 1Z17
View full trial information.
Brain, Glioblastoma
A prospective phase II trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma.
CASE 3313
View full trial information.
Lung
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
SWOG 1400
View full trial information.
Breast
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer.
NFI 1114
View full trial information.
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.
Advertisement
Advertisement
Findings could help with management of a common, dose-limiting side effect
Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression
Treatment involved checkpoint inhibitor, surgery and intravesical therapy
Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials
Multi-specialty coordination essential for improving quality of life
Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy
Early intervention helps prevent chronic lymphedema
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management